---
layout: post
title: "Product-Specific Guidance for Testosterone; Revised Draft Guidance for Industry; Availability"
date: 2026-02-05 18:59:03 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-09737
original_published: 2022-05-06 00:00:00 +0000
significance: 8.00
---

# Product-Specific Guidance for Testosterone; Revised Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** May 06, 2022 00:00 UTC
**Document Number:** 2022-09737

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled "Draft Guidance for Testosterone." The revised draft guidance, when finalized, will provide product-specific recommendations on, among other things, the information and data needed to demonstrate bioequivalence (BE) to support abbreviated new drug applications (ANDAs) for testosterone pellet.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/05/06/2022-09737/product-specific-guidance-for-testosterone-revised-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2022-09737

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
